Omentin-1 vs Davunetide
Head-to-head comparison of Omentin-1 (Omentin-1 (Intelectin-1, ITLN1)) and Davunetide (Activity-Dependent Neuroprotective Protein fragment NAP (NAPVSIPQ)) — benefits, dosing, side effects, research data, and where to buy.
Research Score
| Property | Omentin-1 | Davunetide |
|---|---|---|
| Category | Diabetes & Metabolic | Cognitive Enhancement |
| Full Name | Omentin-1 (Intelectin-1, ITLN1) | Activity-Dependent Neuroprotective Protein fragment NAP (NAPVSIPQ) |
| Molecular Weight | ~35 kDa | 796.9 Da |
| Half-Life | hours | short; minutes to low hours |
| Amino Acids | 313 | 8 |
| Typical Dose | No approved human dose; research use only | 1-10 mg/day research range |
| Route | IV|SC | Intranasal |
| Purity | ≥98% | ≥98% |
| Studies Count | 82 | 40 |
| Research Status | Pre-clinical | Clinical/Pre-clinical |
Omentin-1 Benefits
- ✓insulin sensitivity
- ✓glucose uptake
- ✓lipid handling
Davunetide Benefits
- ✓neuroprotection
- ✓microtubule support
- ✓attention support
- ✓memory preservation
Omentin-1 Dosing
not established|not established
Davunetide Dosing
intranasal research dosing|1-10 mg per dose in trials/preclinical work|once or twice daily
Omentin-1 Side Effects
- ⚠unknown
- ⚠immunogenicity risk
Davunetide Side Effects
- ⚠nasal irritation
- ⚠headache
- ⚠limited efficacy in late-stage trials
Research Overview
Omentin-1
Lower omentin-1 levels are often associated with obesity, insulin resistance, and metabolic syndrome. Research continues on its use as a biomarker and as a mechanistic lead for AMPK-linked metabolic interventions.
Davunetide
Preclinical work showed davunetide can protect neurons, preserve synaptic structure, and improve performance in memory tasks. Human trials largely focused on neurodegenerative disease outcomes rather than stand-alone nootropic use, but the literature supports CNS activity.
Ready to buy?
Find both peptides from our verified, lab-tested vendors with purity certificates and third-party testing.